Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis
Background Achieving target coverage levels for mass drug administration (MDA) is essential to elimination and control efforts for several neglected tropical diseases (NTD). To ensure program goals are met, coverage reported by drug distributors may be validated through household coverage surveys that rely on respondent recall. This is the first study to assess accuracy in such surveys. Methodology/Principal Findings Recall accuracy was tested in a series of coverage surveys conducted at 1, 6, and 12 months after an integrated MDA in Togo during which three drugs (albendazole, ivermectin, and praziquantel) were distributed. Drug distribution was observed during the MDA to ensure accurate recording of persons treated during the MDA. Information was obtained for 506, 1131, and 947 persons surveyed at 1, 6, and 12 months, respectively. Coverage (defined as the percentage of persons taking at least one of the MDA medications) within these groups was respectively 88.3%, 87.4%, and 80.0%, according to the treatment registers; it was 87.9%, 91.4% and 89.4%, according to survey responses. Concordance between respondents and registers on swallowing at least one pill was >95% at 1 month and >86% at 12 months; the lower concordance at 12 months was more likely due to difficulty matching survey respondents with the year-old treatment register rather than inaccurate responses. Respondents generally distinguished between pills similar in appearance; concordance for recall of which pills were taken was over 80% in each survey. Significance In this population, coverage surveys provided remarkably consistent coverage estimates for up to one year following an integrated MDA. It is not clear if similar consistency will be seen in other settings, however, these data suggest that in some settings coverage surveys might be conducted as much as one year following an MDA without compromising results. This might enable integration of post-MDA coverage measurement into large, multipurpose, periodic surveys, thereby conserving resources.
References
[1]
Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, et al. (2007) Control of neglected tropical diseases. N Engl J Med 357: 1018–1027. pmid:17804846 doi: 10.1056/nejmra064142
[2]
2006) Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. In: Organization WH, editor. Geneva, Switzerland: WHO Press.
[3]
2005) Immunization coverage cluster survey—Reference manual In: Organization WH, editor. WHO/IVB/0423. Geneva, Switzerland: World Health Organization.
[4]
Baker MC, Krotki K, Sankara DP, Trofimovich L, Zoerhoff KL, et al. (2013) Measuring treatment coverage for neglected tropical disease control programs: analysis of a survey design. Am J Epidemiol 178: 268–275. doi: 10.1093/aje/kws468. pmid:23860563
[5]
Worrell C, Mathieu E (2012) Drug coverage surveys for neglected tropical diseases: 10 years of field experience. Am J Trop Med Hyg 87: 216–222. doi: 10.4269/ajtmh.2012.12-0167. pmid:22855750
[6]
Setel PW, Macfarlane SB, Szreter S, Mikkelsen L, Jha P, et al. (2007) A scandal of invisibility: making everyone count by counting everyone. Lancet 370: 1569–1577. pmid:17992727 doi: 10.1016/s0140-6736(07)61307-5
[7]
Langsten R, Hill K (1998) The accuracy of mothers' reports of child vaccination: evidence from rural Egypt. Soc Sci Med 46: 1205–1212. pmid:9572610 doi: 10.1016/s0277-9536(97)10049-1
[8]
Odusanya OO, Alufohai EF, Meurice FP, Ahonkhai VI (2008) Determinants of vaccination coverage in rural Nigeria. BMC Public Health 8: 381. doi: 10.1186/1471-2458-8-381. pmid:18986544
[9]
Ramakrishnan R, Rao TV, Sundaramoorthy L, Joshua V (1999) Magnitude of recall bias in the estimation of immunization coverage and its determinants. Indian Pediatr 36: 881–885. pmid:10744865
[10]
Bureau UC Census and Survey Processing System (CSPro).
[11]
Cantey PT, Rao G, Rout J, Fox LM (2010) Predictors of compliance with a mass drug administration programme for lymphatic filariasis in Orissa State, India 2008. Trop Med Int Health 15: 224–231. doi: 10.1111/j.1365-3156.2009.02443.x. pmid:20002615
[12]
Weil GJ, Sethumadhavan KV, Santhanam S, Jain DC, Ghosh TK (1988) Persistence of parasite antigenemia following diethylcarbamazine therapy of bancroftian filariasis. Am J Trop Med Hyg 38: 589–595. pmid:3079315
[13]
Mepukori N (2013) Digging deeper into pregnancy taboos among Togolese women. Diaries From the Field Blog: Duke Global Health Institute.
[14]
Gyapong JO, Chinbuah MA, Gyapong M (2003) Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis. Trop Med Int Health 8: 1093–1101. pmid:14641844 doi: 10.1046/j.1360-2276.2003.01142.x
[15]
Knipes AK, Bathiri SA, Nyaku M, Chapleau G, Mathieu E (2014) Estimating accuracy of participant recall following an integrated mass drug administration for neglected tropical diseases American Society of Tropical Medicine and Hygeine 63rd Annual Meeting. New Orleans, LA, USA.